Biogen Inc.

Symbol: BIIB

NASDAQ

239.29

USD

Market price today

  • 23.7031

    P/E Ratio

  • 0.9946

    PEG Ratio

  • 34.67B

    MRK Cap

  • 0.00%

    DIV Yield

Biogen Inc. (BIIB) Stock Price & Analysis

Shares Outstanding

144.9M

Gross Profit Margin

0.75%

Operating Profit Margin

0.14%

Net Profit Margin

0.15%

Return on Assets

0.05%

Return on Equity

0.10%

Return on Capital Employed

0.06%

Company general description and statistics

Sector: Healthcare
Industry: Drug Manufacturers—General
CEO:Mr. Christopher A. Viehbacher
Full-time employees:8725
City:Cambridge
Address:225 Binney Street
IPO:1991-09-17
CIK:0000875045

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.

General Outlook

In simple terms, Biogen Inc. has 144.898 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep 0.751% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 0.138%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of 0.146%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust 0.052% return, is a testament to Biogen Inc.'s adeptness in optimizing resource deployment. Biogen Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.104%. Furthermore, the proficiency of Biogen Inc. in capital utilization is underscored by a remarkable 0.060% return on capital employed.

Stock Prices

Biogen Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $234.76, while its low point bottomed out at $231.11. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Biogen Inc.'s stock market.
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2023?

There are stock number shares outstanding of Biogen Inc. (BIIB) on the NASDAQ in 2023.

What is P/E ratio of enterprise in 2023?

The current P/E ratio of enterprise is 23.703 in 2023.

What is the ticker symbol of Biogen Inc. stock?

The ticker symbol of Biogen Inc. stock is BIIB.

What is company IPO date?

IPO date of Biogen Inc. is 1991-09-17.

What is company current share price?

Current share price is 239.290 USD.

What is stock market cap today?

The market cap of stock today is 34672642420.000.

What is PEG ratio in 2023?

The current 0.995 is 0.995 in 2023.

What is the number of employees in 2023?

In 2023 the company has 8725.